title: Treatment of saphenous vein graft lesions with paclitaxel- and sirolimus-eluting stents: comparison of short- and long-term clinical outcomes.
abstract: OBJECTIVE
  The purpose of this study was to compare treatment of saphenous vein graft (SVG) lesions with paclitaxel-eluting (PES) and sirolimus-eluting stents (SES) in daily practice with regard to short- and long-term clinical outcomes.
  
  
  METHODS
  Between August 2002 and September 2006, a total of 71 patients with SVG lesions who were implanted PES or SES with percutaneous coronary intervention in our center were evaluated retrospectively. Forty-six patients with PES (PES group) were compared to twenty-five patients treated with SES (SES group) in terms of in-hospital, 30-day, six-months and 1-year clinical outcomes. Statistical analyses were performed using Chi-Square statistics or Fisher's exact and independent sample t test. Survival analysis was done using Kaplan-Meier method and log-rank test.
  
  
  RESULTS
  Baseline clinical characteristics were similar in both groups except for a tendency toward a lower age in the SES group. No statistically significant difference was found between two groups by means of lesion and procedural characteristics. All clinical outcomes at 30-day, 6-month and 1-year after the interventions were similar in both groups. Early stent thrombosis was detected in one patient (2.2%) of PES group (p=0.65). Late stent thrombosis was not observed in both groups. The rate of major adverse cardiac events at 1-year was 8.7% in the PES group and 16% in the SES group (p=0.44).
  
  
  CONCLUSIONS
  Short-and long-term clinical outcomes of PES and SES in the treatment of SVG lesions are similar. The results of our study showed that both drug-eluting stents are effective and safe in real-world patient with diseased SVGs.
authors.affiliation: Department of Cardiology, Florence Nightingale Hospital, Istanbul, Turkey.
authors.forename: Selçuk
authors.initials: S
authors.lastname: Görmez
authors.forename: Refik
authors.initials: R
authors.lastname: Erdim
authors.forename: Onur
authors.initials: O
authors.lastname: Erdoğmuş
authors.forename: Murat
authors.initials: M
authors.lastname: Civan
authors.forename: Alp Burak
authors.initials: AB
authors.lastname: Catakoğlu
authors.forename: Murat
authors.initials: M
authors.lastname: Gülbaran
authors.forename: Cemşid
authors.initials: C
authors.lastname: Demiroğlu
authors.forename: Vedat
authors.initials: V
authors.lastname: Aytekin
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D054855:Drug-Eluting Stents; D005260:Female; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006760:Hospitalization; D006801:Humans; D053208:Kaplan-Meier Estimate; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology*; D011859:Radiography; D012189:Retrospective Studies; D012501:Saphenous Vein / Q000473:pathology / Q000601:surgery*; D012720:Severity of Illness Index; D020123:Sirolimus / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus